- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America
- Join Join
Americans for Safe Access Co-Author’s Study in JAMA on Cannabidiol Products
Washington, DC - A new study published this week in JAMA found that nearly 70 percent of all cannabidiol (CBD) products sold online are either over or under labeled, causing potential serious harm to its consumers. The study, co-authored by Jahan Marcu, Ph.D, American’s for Safe Access’ (ASA) Chief Science Officer and Director of Patient Focused Certification (PFC), analyzed 84 CBD products available online from 31 companies.
“This is a wake up call for the CBD industry to standardize their products,” said Dr. Marcu, “CBD product manufacturers need to adopt best practices and accept guidance from AHPA and other groups to improve consistency and safety for consumers. Reaching compliance with existing standards for cannabis-products could help address this issue.”
Analysis from jointly PFC certified & ISO17025 accredited laboratories showed 43 percent of products contained more CBD than indicated on the label, 26 percent contained less, and 31 percent were accurately labeled (within 10 percent). This degree of mislabeling poses safety and efficacy issues for consumers, particularly given the fact that these unapproved CBD formulations are often used to treat children with intractable epilepsy.
In recent years, there has been an increased interest in the medicinal use of CBD, a chemical that naturally occurs the in cannabis plant (aka “marijuana”). There is interest in CBD as a medicine because there is some evidence that it has medical benefits, but it does not make people feel “high” and there is no indication that CBD, by itself, is abused. Recent research has shown potential therapeutic effects of CBD for young children with rare seizure disorders, and patients in states where cannabis or CBD have been legalized report using it for a variety of health conditions. Business experts estimate that the market for CBD products will grow to more than $2 billion in consumer sales within the next three years. While interest in this area continues to grow, little has been done to ensure regulation and oversight of the sale of products containing CBD. The primary reason for this is that CBD is currently classified as a Schedule I controlled dangerous substance by the DEA, despite having been legalized for medicinal use in many states. Thus, many people do not have access to stores that sell CBD products and instead rely on online retailers to purchase CBD products.
Dr. Marcu has more than 10 years of experience in cannabis pharmacology and chemistry, and is an expert on medical cannabis standards. He is co-author of The American Herbal Pharmacopoeia Cannabis Inflorescence Standards of Identity, Analysis, and Quality Control and other peer-reviewed reports published by Americans for Safe Access.
ASA was founded in 2002, as a vehicle for patients to advocate for the acceptance of cannabis as medicine. With over 100,000 active members in all 50 states, ASA is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political, social and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, research, grassroots empowerment, advocacy and services for patients, governments, medical professionals, and medical cannabis providers.
The Patient Focused Certification (PFC) program is a non-profit, peer reviewed, third party certification program for the medical cannabis industry and the nation’s only certification program for the AHPA and AHP Standards. Offered by ASA, PFC is what patients, caregivers, healthcare providers, companies, and regulators can depend on to identify reliable, high-quality medical cannabis products and services.
For additional information about ASA, please click here: http://www.safeaccessnow.org/
For additional information about the PFC Program, please click here: http://patientfocusedcertification.org
For reporters interesting in learning more, or to receive a full copy of the article please contact Debbie Churgai at 240-893-2153 or by email at [email protected].